Breast Cancer ESMO 2024 Highlights: Key Studies Discussed NATALEE, KEYNOTE 522, DESTINY-Breast12

Welcome to the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Paolo Tarantino from the Dana-Farber Cancer Institute to discuss the latest highlights from ESMO 2024, focusing on groundbreaking studies in breast cancer.

 

Join us as we dive into three key abstracts that have the potential to impact current clinical practice:

1.⁠ NATALEE Trial: Discover how the addition of ribociclib to endocrine therapy has shown improved invasive disease-free survival in early-stage breast cancer, including node-negative patients. Ribociclib was recently approved for this indication, and we discuss its implications for patient care.

2.⁠ ⁠Keynote 522 Update: We explore the updated results demonstrating an overall survival benefit with the perioperative use of pembrolizumab in combination with neoadjuvant chemotherapy for early-stage triple-negative breast cancer. This regimen continues to be a standard of care.

3.⁠ ⁠DESTINY Breast-12: Learn about the promising intracranial activity of trastuzumab durextecan in HER2-positive breast cancer patients with brain metastases, showcasing its potential to change treatment trajectories.

 

Tune in for an insightful discussion that highlights the evolving landscape of breast cancer treatment and offers hope for patients. Don't forget to check out our other episodes covering GI, lung, and GU cancer conference highlights!

 

Subscribe for more updates and insights from the Oncology Brothers!

 

Website: http://www.oncbrothers.com/

 

Twitter: https://twitter.com/oncbrothers

 

Contact us at info@oncbrothers.com